RXi Pharmaceuticals to Present New Preclinical Data Demonstrating the Robust Performance of its RNAi Therapeutics Platform

WORCESTER, Mass.--(BUSINESS WIRE)--Mar 25, 2010 - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco, Ph.D., Vice President of Pharmaceutical Development, will be presenting at the 3rd International Scar Club Meeting in Montpellier, France on March 26, 2010. The presentation will not be webcast.


 

Dr. Pavco's presentation describes new preclinical data exemplifying the performance of RXi's proprietary self-delivering rxRNA (sd-rxRNA™) compounds in an in vivo model of compromised skin. Data generated using a fluorescently-tagged sd-rxRNA™ compound demonstrate spontaneous cellular uptake into dermal cells and a significant, sustained and reproducible silencing of the targeted mRNA. The data presented establish the efficacy of locally-administered sd-rxRNA™ in animal models and support the potential use of these novel compounds for clinical applications where direct or local administration is possible.


 

"We are very encouraged with the substantial progress we have made with our therapeutic platform, especially our proprietary sd-rxRNA™,” said Noah D. Beerman, President and Chief Executive Officer of RXi. “Delivery remains one of the most important objectives in our efforts to advance RNAi therapeutics into patients. Our demonstration that sd-rxRNA™ compounds efficiently enter cells in vivo and effect significant gene silencing without the need for an additional delivery vehicle is an important advancement for RXi in its progression toward the clinic.”


 

About RNAi and sd-rxRNA™


 

Regarded as a revolutionary discovery in biology, RNAi is a naturally occurring mechanism whereby short, double-stranded RNA molecules interfere with the expression of genes in living cells. This mechanism has the potential to be harnessed to “silence” or specifically block the production of disease-causing proteins before they are made. This technology can potentially be used to treat human diseases by “turning-off” genes that lead to disease in the first place. RXi Pharmaceuticals is using RNAi technology to develop RNA-derived molecules targeting disease-causing genes.


 

sd-rxRNA™ is a proprietary technology recently developed at RXi which enables the efficient delivery of RNAi compounds without the requirement of an additional delivery vehicle.


 

About RXi Pharmaceuticals Corporation


 

RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi compounds and advanced delivery methods. RXi uses its own version of RNAi compounds -- rxRNA™ -- that provide an advanced alternative to conventional small interfering RNAs (siRNAs) and define the next generation of RNAi technology. rxRNA compounds are designed specifically for therapeutic use and contain many of the properties required to progress RNAi based drugs into the clinic. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong early intellectual property position in RNAi chemistry and delivery. http://www.rxipharma.com


 

Forward-Looking Statements


 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, plan and future development of RXi Pharmaceutical Corporation's products and technologies. These forward-looking statements about future expectations, plans and prospects of the development of RXi Pharmaceutical Corporation's products and technologies involve significant risks, uncertainties and assumptions, including the risk that the development of our RNAi-based therapeutics may be delayed or may not proceed as planned and we may not be able to complete development of any RNAi-based product, the risk that the FDA approval process may be delayed for any drugs that we develop, risks related to development and commercialization of products by our competitors, risks related to our ability to control the timing and terms of collaborations with third parties and the possibility that other companies or organizations may assert patent rights that prevent us from developing our products. Actual results may differ materially from those RXi Pharmaceuticals Corporation contemplated by these forward-looking statements. RXi Pharmaceuticals Corporation does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.


 

 


 


 

Contact: RXi Pharmaceuticals Corporation

Investor Relations:

508-929-3615

ir@rxipharma.com

or

Investors:

S. A. Noonan Communications

Susan Noonan, 212-966-3650

susan@sanoonan.com

or

Media:

Rx Communications Group

Eric Goldman, 917-322-2563

egoldman@rxir.com


 

 


 

 

Posted: March 2010

View comments

Hide
(web5)